Alexandra Lesnick, Tina L Samuels, Donna Seabloom, Beverly Wuertz, Abhilash Ojha, Davis Seelig, Frank Ondrey, Timothy S Wiedmann, Chris Hogan, Emma Torii, Hui Ouyang, Ke Yan, Guilherme J M Garcia, Jonathan M Bock, Nikki Johnston
OBJECTIVES: Approximately 25% of Americans suffer from laryngopharyngeal reflux (LPR), a disease for which no effective medical therapy exists. Pepsin is a predominant source of damage during LPR and a key therapeutic target. Fosamprenavir (FOS) inhibits pepsin and prevents damage in an LPR mouse model. Inhaled FOS protects at a lower dose than oral; however, the safety of inhaled FOS is unknown and there are no inhalers for laryngopharyngeal delivery. A pre-Good Lab Practice (GLP) study of inhaled FOS was performed to assess safety and computational fluid dynamics (CFD) modeling used to predict the optimal particle size for a laryngopharyngeal dry powder inhaler (DPI)...
February 2024: Laryngoscope Investigative Otolaryngology